Literature DB >> 33718815

Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear-cell renal cell carcinoma.

Akihito Okazaki1, Toshiki Kijima1, Philipp Schiller1, Natsumi Ishikawa1, Hirotaka Fuchizawa1, Kohei Takei1, Issei Suzuki1, Kazumasa Sakamoto1, Toyonori Tsuzuki2, Takao Kamai1.   

Abstract

INTRODUCTION: The spontaneous regression of metastases, which mostly occurs after surgical resection of the primary tumor, has been described in various malignancies, including renal cell carcinoma. The involvement of the host immune system is currently postulated as the underlying mechanism. CASE
PRESENTATION: We present a case of metastatic clear-cell renal cell carcinoma that achieved complete spontaneous regression of multiple pulmonary metastases preceded by normalization of serum immune markers after cytoreductive nephrectomy. The patient remained disease free for 3 years without any systemic therapy, suggesting that postoperative normalization of serum immune markers may indicate recovery of the host immune system, which prevents tumor recurrence.
CONCLUSION: Monitoring of serum immune markers may be useful to identify patients with recovered immune function and, therefore, may not require systemic therapy. Similarly, the case suggests a potential role of cytoreductive nephrectomy in the contemporary management of metastatic renal cell carcinoma.
© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Entities:  

Keywords:  immunity; inflammation; nephrectomy; renal cell carcinoma; spontaneous neoplasm regression

Year:  2020        PMID: 33718815      PMCID: PMC7924083          DOI: 10.1002/iju5.12252

Source DB:  PubMed          Journal:  IJU Case Rep        ISSN: 2577-171X


  21 in total

1.  The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.

Authors:  Jun Teishima; Kohei Kobatake; Shunsuke Shinmei; Shogo Inoue; Tetsutaro Hayashi; Shinya Ohara; Koji Mita; Yasuhisa Hasegawa; Satoshi Maruyama; Mitsuru Kajiwara; Masanobu Shigeta; Hideki Mochizuki; Hiroyuki Moriyama; Seiji Fujiwara; Akio Matsubara
Journal:  Urol Oncol       Date:  2017-08-01       Impact factor: 3.498

2.  Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis.

Authors:  Bohuslav Melichar; Jaroslava Vanecková; Petr Morávek; Hana Urminská; Miroslav Podhola
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

3.  Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review).

Authors:  Sante Basso Ricci; Ugo Cerchiari
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

Review 4.  Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.

Authors:  Daniel D Shapiro; E Jason Abel
Journal:  Curr Opin Urol       Date:  2019-09       Impact factor: 2.309

5.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

6.  The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma.

Authors:  Jun Teishima; Kohei Kobatake; Hiroyuki Kitano; Hirotaka Nagamatsu; Kousuke Sadahide; Keisuke Hieda; Shunsuke Shinmei; Koichi Shoji; Shogo Inoue; Tetsutaro Hayashi; Yoji Inoue; Shinya Ohara; Koji Mita; Akio Matsubara
Journal:  BJU Int       Date:  2015-09-25       Impact factor: 5.588

Review 7.  EORTC-GU group expert opinion on metastatic renal cell cancer.

Authors:  Theo M de Reijke; Joaquim Bellmunt; Hein van Poppel; Sandrine Marreaud; Matti Aapro
Journal:  Eur J Cancer       Date:  2009-01-20       Impact factor: 9.162

8.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

9.  Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.

Authors:  Akinori Nukui; Akinori Masuda; Hideyuki Abe; Kyoko Arai; Ken-Ichiro Yoshida; Takao Kamai
Journal:  BMC Cancer       Date:  2017-05-25       Impact factor: 4.430

10.  Checkpoint molecule PD-1-assisted CD8+ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Authors:  Jiaxi Yao; Wei Xi; Yanjun Zhu; Hang Wang; Xiaoyi Hu; Jianming Guo
Journal:  Cancer Manag Res       Date:  2018-09-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.